Protagenic Therapeutics, Inc.\new Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
Protagenic Therapeutics, Inc.\new (PTIX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of 25.20% for the 12-month period ending 2026-03-31, per its 10-K filed 2026-08-14.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-08-14
- Protagenic Therapeutics, Inc.\new effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2026 was 25.20%.
- Protagenic Therapeutics, Inc.\new effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2025 was -4.00%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|
| 2026-03-31 | 25.20% 10-K · filed 2026-08-14 |
| 2025-03-31 | -4.00% 10-K · filed 2026-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |